In the session, the price of Moderna rose 8.3% to US$130.72.
The two companies then agreed to work together on the development and commercialization of the vaccine, as well as share the costs and benefits equally.
“We have been collaborating with Merck on PCV since 2016, and together we have made significant progress in advancing mRNA-4157 as an investigational personalized cancer treatment used in combination with KEYTRUDA,” said Dr. Stephen Hoge, President of Moderna.
The two companies also said they are on track to report data from the phase 2 trial of mRNA-4157/V940 in combination with Keytruda for high-risk melanoma patients in the fourth quarter of this year.
With the market size of the COVID-19 Vaccines projected to contract in the coming years from the levels seen in 2021, Moderna has pinned its hopes on other shots, including shots against the flu and respiratory syncytial virus.
The cancer vaccine is tailored to each patient to generate T cells, a key part of the body’s immune response, based on a tumor’s specific mutational signature.
Source: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
